日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis

解析乳腺癌亚型中的 ERBB 信号——基于模型的分析

Svenja Kemmer, Mireia Berdiel-Acer, Eileen Reinz, Johanna Sonntag, Nooraldeen Tarade, Stephan Bernhardt, Mirjam Fehling-Kaschek, Max Hasmann, Ulrike Korf, Stefan Wiemann, Jens Timmer

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy

抗 HER2/3 联合治疗引起的腹泻毒性机制研究

Annie Moisan, Francesca Michielin, Wolfgang Jacob, Sven Kronenberg, Sabine Wilson, Blandine Avignon, Régine Gérard, Fethallah Benmansour, Christine McIntyre, Georgina Meneses-Lorente, Max Hasmann, Andreas Schneeweiss, Martin Weisser, Céline Adessi

Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions

生理条件下曲妥珠单抗和内源性人免疫球蛋白易受影响的化学修饰位点的评估

Ingrid Schmid, Lea Bonnington, Monika Gerl, Katrin Bomans, Anna Louisa Thaller, Katharina Wagner, Tilman Schlothauer, Roberto Falkenstein, Boris Zimmermann, Jürgen Kopitz, Max Hasmann, Frieder Bauss, Markus Haberger, Dietmar Reusch, Patrick Bulau

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

直接雌激素受体 (ER)/HER 家族串扰介导 ER+ 乳腺癌对鲁瑞珠单抗和帕妥珠单抗的敏感性

Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Martin Weisser, Birgit Bossenmaier

Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3

帕妥珠单抗抵消了 ErbB2 对 ErbB3 降解的抑制作用

Malgorzata Magdalena Sak, Monika Szymanska, Vibeke Bertelsen, Max Hasmann, Inger Helene Madshus, Espen Stang

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab

帕妥珠单抗可增强 17-AAG 诱导的 ErbB2 降解,帕妥珠单抗与曲妥珠单抗联合使用可进一步增强这一效果

Juliana Bentes Hughes, Marianne Skeie Rødland, Max Hasmann, Inger Helene Madshus, Espen Stang